ScholarWorks@Hanyang University: Shin, Jinho

Detailed Information

Shin, Jinho (신진호)

COLLEGE OF MEDICINE (DEPARTMENT OF INTERNAL MEDICINE)

Research Area

Tel 02-2290-8308
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

hypertension:43||Hypertension:38||Blood pressure:19||Asia:17||blood pressure:14||mortality:8||amlodipine:7||Blood pressure monitoring:6||Guidelines:6||Echocardiography:6||Ambulatory:6||blood pressure control:6||Cardiovascular risk:6||blood pressure variability:5||guidelines:5||Atherosclerosis:5||Awareness:5||Arterial stiffness:5||Treatment:5||Electrocardiography:5||Pulse wave velocity:4||home blood pressure monitoring:4||ambulatory:4||Ambulatory blood pressure monitoring:4||Left ventricular function:4||Coronary artery disease:4||Percutaneous coronary intervention:4||fimasartan:4||Metabolic syndrome:4||Antihypertensive treatment:4||combination therapy:4||White coat hypertension:4||home blood pressure:4||Prevalence:4||Myocardial infarction:4||COVID19:4||Hypertrophy:3||Hemodialysis:3||cardiovascular mortality:3||Lifestyle:3||Sodium:3||ambulatory blood pressure monitoring:3||emergency department:3||Control:3||Blood Pressure Monitoring:3||hypertensive crisis:3||Measurement:3||losartan:3||Korea:3||obesity:3||validated blood pressure monitoring device:3||Obesity:3||Systemic lupus erythematosus:3||cardiovascular risk:3||atrial fibrillation:3||central blood pressure:2||sphygmomanometers:2||stroke:2||Angiotensin receptor blocker:2||changes in body fat:2||target blood pressure:2||telmisartan:2||chlorthalidone:2||clinical practice:2||cognitive dysfunction:2||Home blood pressure monitoring:2||combination:2||variability:2||관상동맥 질환:2||Ambulatory blood pressure:2||cost:2||Atrial fibrillation:2||dementia:2||diagnosis:2||diagnostic errors:2||Elderly:2||Compliance:2||dyslipidemia:2||economics:2||Empathy:2||elderly:2||Subclinical atherosclerosis:2||Antihypertensive drugs:2||Cardiovascular complications:2||epidemiological factors:2||epidemiology:2||essential hypertension:2||Exercise:2||Insulin resistance:2||Intravascular ultrasonography:2||Practice guideline:2||guideline:2||KNHANES:2||Prematrure:2||Prognosis:2||home blood pressure monitor:2||Prospective:2||Coronary artery calcium (CAC) score:2||Fimasartan:2||Blood pressure measurement:2||left ventricular:2||lowdose:2||Blood pressure monitoring, ambulatory:2||management:2||Blood pressure variability:2||Renal dialysis:2||Body composition:2||ambulatory blood pressure:2||morning blood pressure surge:2||Guideline:2||angiotensin receptor blocker:2||neoplasms:2||Resistant hypertension:2||MOSSSS:2||AsiaBP@Home study:2||obesity paradox:2||Masked hypertension:2||Risk assessment:2||HOPE Asia Network:2||Risk factors:2||arterial stiffness:2||Rural community:2||Asian:2||bioimpedance method:2||Albuminuria:2||primary care issues:2||Diuretics:2||Screening:2||Heart failure:2||Mortality:2||Aging:2||cardiovascular disease:2||cardiovascular diseases:2||rosuvastatin:2||Home study:1||Hope Asia:1||HyperGEN study:1||Hypertension incidence:1||Hypertensive urgency:1||Hypertrophy, left ventricular:1||Hypotension:1||Instent restenosis:1||Incidence:1||Independent predictor:1||Infection:1||Infective endocarditis:1||Insulin Resistance:1||Iodine intake:1||Korean Men:1||Korean population:1||LA (left atrium) angiography:1||LDLC:1||Left Ventricular Hypertrophy:1||Left atrial appendage:1||Left ventricle:1||Left ventricular:1||Left ventricular hypertrophy:1||Leriche syndrome:1||Lifestyle factors:1||Lipid profiles:1||Longitudinal study:1||Losartan:1||Manual office blood pressure:1||Masked uncontrolled hypertension:1||Mediator:1||Metabolic syndrome X:1||Minnesota code classification:1||Mitral Regurgitation:1||Monotherapy:1||Most recent alcohol consumption:1||Motivational interviewing:1||Motor activity:1||Myocardial ischemia:1||Myxoma:1||Nocturnal hypertension:1||Nonreactive tests:1||Online campaign:1||Optical coherence tomography (OCT):1||Organ damage:1||Organdamage:1||Oscillometry:1||Out of office blood pressure measurements:1||P2Y(12):1||Pandemic:1||Patientcentered care:1||Perindopril:1||Peripheral arterial disease:1||Peripheral blood stem cell:1||Pfizer:1||Platelet aggregation inhibitors:1||Plethysmography:1||Postmenopausal women:1||Potassium:1||Prasugrel:1||Predictor:1||Prevention and control:1||Primary prevention:1||Prospective cohort study:1||Pseudoresistance:1||Psychosocial intervention:1||Public health:1||Pulmonary:1||Pulmonary function:1||Pulmonary hypertension:1||Purinergic P2Y receptor antagonists:1||Quality controls:1||Radial artery:1||Refractory hypertension:1||Reninangiotensin system:1||Repeated alcohol consumption measurements:1||Republic of Korea:1||Residual method:1||Reverse Dipping Pattern:1||Rheumatoid arthritis:1||Risk Factors:1||Risk factor:1||Rosuvastatin:1||Rural population:1||SARS:1||SARSCoV2:1||STT wave abnormality:1||Sample entropy:1||Seaweed:1||Selfmonitoring:1||Selfreport questionnaire:1||Sensitivity and specificity:1||Sepsis:1||Serum 25(OH)D:1||Severe acute respiratory syndrome coronavirus:1||Sex:1||Single nucleotide polymorphism:1||Singlenucleotide polymorphisms:1||Sleep:1||Smartphone:1||Smoking:1||Social support:1||Sodium bicarbonate:1||Sodium chloride:1||Sodium intake:1||Sphygmomanometers:1||Spirornetry:1||Spondylodiskitis:1||Standardization:1||Stress:1||Stroke:1||Subclinical hypothyroidism:1||Subclinical vascular damage:1||Subsyndromal depression:1||Takotsubo cardiomyopathy:1||Target blood pressure:1||Testosterone:1||Therapeutics:1||Ticagrelor:1||Transcatheter closure:1||Translation:1||Treatment adherence and compliance:1||Troponin I:1||Type VI dual LAD anomaly:1||Unilateral Pulmonary Edema:1||Urine specimen collection:1||Vascular Stiffness:1||Vascular closure devices:1||Vibroacoustic stimulation test:1||Visittovisit variability:1||Waist circumference:1||Weight loss:1||Whitecoat effect:1||Workplace:1||Young adult:1||acute severe hypertension:1||addon therapy:1||adherence:1||adiponectin:1||alcohol:1||ambient temperature:1||angiotensin II type 1 receptor blockers:1||angiotensinconverting enzyme inhibitor:1||angiotension II type 1 receptor blockers:1||anthropometry:1||antihypertensive:1||antihypertensive agent:1||antihypertensive agents:1||antihypertensive medication:1||aortic pressure:1||arrhythmia:1||atorvastatin:1||auscultation:1||baPWV:1||bedtime dosing:1||blood pressure change:1||blood pressure determination:1||blood pressure monitoring:1||body fat distribution:1||brachial BP:1||calcium channel blocker:1||candesartan:1||cardiovascular events:1||cardiovascular outcome:1||central BP:1||central obesity:1||clinical management of high blood pressure (HBP):1||cohort:1||cohort study:1||combination drug therapy:1||community:1||control blood pressure:1||coronary heart disease:1||crosssectional study:1||cumulative average alcohol consumption:1||development:1||diastolic:1||dietary pattern:1||disaster:1||diversity:1||drug combination:1||earlyonset hypertension:1||elderly population:1||electronic:1||environment:1||epidemiologic survey:1||ezetimibe:1||fixeddose combination:1||flavonoids:1||gender:1||glomerular filtration rate:1||health status disparities:1||health survey:1||healthrelated quality of life:1||heart failure with preserved:1||heart rate:1||high BP:1||home BP measurement:1||home blood pressure (HBPM):1||hydrochlorothiazide:1||hypercholesterolemia:1||hypertensionmediated organ damage:1||hypertrophy:1||income:1||initiative:1||irbesartan:1||left ventricular hypertrophy:1||longitudinal study:1||lowdose combination:1||lowrisk population:1||lowrisk populations:1||masked hypertension:1||measured home heart rate:1||measurement:1||menopause:1||mental health:1||metabolic syndrome:1||monotherapy:1||morning:1||morning blood pressure:1||myocardial infarction:1||nebivolol:1||neck:1||nocturnal SBP:1||nocturnal blood pressure:1||nocturnal hypertension:1||obstructive sleep apnea:1||office blood pressure:1||oldest old:1||oscillometry:1||osteoporosis:1||outofoffice blood pressure:1||pathologic Q wave:1||perindopril:1||peripheral BP:1||personalized approach:1||pharmacologic (drug) therapy:1||physical examination:1||placebo:1||prevalence:1||prospective:1||proteinuria:1||protocol:1||pulmonary function test:1||pulmonary hypertension:1||pulse rate:1||recent alcohol consumption:1||reduced ejection fraction:1||resistant hypertension:1||resting heart rate:1||rosuvastatin calcium:1||salt sensitivity:1||self&:1||sex differences:1||smoothness index:1||sodium intake:1||subclasses:1||subclinical atherosclerosis:1||thiazides:1||treatment and diagnosis:1||troughpeak ratio:1||type 2 diabetes mellitus:1||urinary sodium excretion:1||validation:1||valsartan:1||waist circumference:1||급성신부전:1||대사 증후군:1||동맥경화:1||목표혈압:1||본태성 고혈압:1||사회적 지지:1||스트레스:1||식염수:1||심박변이도:1||아세틸시스테인:1||인슐린 저항성:1||전신홍반루푸스:1||조영제:1||중탄산염:1||진료지침:1||테스토스테론:1||항고혈압약제:1||#8208:1||혈관내 초음파:1||2019 novel coronavirus:1||24hour blood pressure:1||ACE inhibitor:1||ACE2:1||Abdominal:1||Abdominal aorta:1||Abdominal obesity:1||Acetylcysteine:1||Acute Myocardial Infarction:1||Acute coronary syndrome:1||Acute coronary syndrome (ACS):1||Acute kidney failure:1||Adherence:1||Adverse effects:1||Age:1||Aged:1||Alcohol:1||Alcohol consumption trajectory:1||Algorithms:1||Amlodipine:1||Angiotensin converting enzyme 2:1||Angiotensin receptor antagonist:1||Angiotensinconverting enzyme inhibitors:1||Anklebrachial index:1||AnsanAnsung cohort:1||Antihypertensive:1||Antihypertensive Agents:1||Antihypertensive agent:1||Antihypertensive agents:1||Antihypertensive medication:1||Antihypertensives agents:1||Apparent treatment resistant hypertension:1||Approximate entropy:1||Arterial hypertension:1||Arteriosclerosis:1||Asia BP@Home:1||Asia BP@Home study:1||Asian countries:1||Asian patient:1||Asian patients:1||Aspirin:1||Asthma:1||Atrial:1||Atrial Fibrillation:1||Autonomic nervous system diseases:1||Blood Pressure:1||Blood pressure3:1||Bone density:1||Bone mineral density:1||Bosentan:1||Brachialankle pulse wave velocity:1||Breast augmentation:1||CAVAS:1||CRP:1||Calcium:1||Calcium channel blocker:1||Cardiac troponin:1||Cardiometabolic risk factors:1||Cardiometabolic risk factors:1||Cardiomyopathy:1||Cardiovascular Mortality:1||Cardiovascular disease:1||Cardiovascular disease (CVD):1||Cardiovascular diseases:1||Cardiovascular event:1||Carotid intima media thickness:1||Carotid intimamedia thickness:1||Catheter ablation:1||Cerebrovascular accident:1||Characteristics:1||China:1||Chronic disease:1||Chronic kidney disease:1||Chronotherapy:1||Circadian:1||Clinical outcomes:1||Clopidogrel:1||Clopidogrel bisulfate:1||Clopidogrel napadisilate:1||Combination:1||Combination drug therapy:1||Communitybased Cohort:1||Complications:1||Computed tomographic coronary angiography:1||Consultation:1||Contrast media:1||Coronary angiography:1||Coronary vasospasm:1||Dshaped left ventricle:1||Depression:1||Device embolization:1||Diabetes Mellitus:1||Diabetes mellitus:1||Diagnostic accuracy:1||Dietary calcium intake:1||Dietary potassium:1||Dietary sodium:1||Dietary vitamin D:1||Doppler:1||Dyslipidemias:1||E/E′:1||EQ5D:1||Early gastric cancer:1||East Asian patients:1||Eccentricity index:1||Efficacy:1||Elastic modulus:1||Emergency department:1||Epidemiology:1||Epilepsy:1||Essential hypertension:1||Fabry Disease:1||Factor Analysis:1||Fatty liver:1||Fetal heart rate:1||Fibrosis:1||Frail elderly:1||Frailty:1||Gastrectomy:1||Genediet interaction:1||General population:1||Gout:1||Granulocyte colony stimulating factor:1||HDLC:1||HOPEAsia Network:1||Health survey:1||Heart Failure:1||Heart atria:1||Heart rate variability:1||Heart septal defects:1||Hip circumference:1||Histology:1||Home blood pressure:1||

STATISTICS: Total View :4,932,373; Today View :5,689

RSS_1.0 RSS_2.0 ATOM_1.0

222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE